2024 New Breakthrogh~ US patent on xenogeneic urothelial cell therapy on bladder cancer has been issued

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,891,628 entitled, “Method for biomimetic culture of urothelial cells and uses thereof.” invented by co-founders Drs. Chih-Rong, Shyr and Chih-Ping Huang on February 6, 2024.
This patent owned by eXCELL Biotherapeutics INC. is a breakthrough xenogeneic cell-based therapy for treating bladder cancer by harnessing the body’s immune system.

The Japanese Patent has been published on 19 December. Patent No. 7272676 on May 1, 2023. Chinese Patent and Taiwan Patent are still pending. This patent family owned by eXCELL demonstrates the company’s pioneering and leading role in xenogeneic cell cancer immunotherapy field.